GlassScriptPhysician profile
Kim P Scott
NPI 1225020563
$1,215.10
in general payments reported to CMS, 2019-2025
26 companies · $43.48 in 2025
The $43.48 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $176 · 2021: $203 · 2022: $49.48 · 2023: $102 · 2024: $163 · 2025: $43.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $363.90 | 2019-2021 | |
| Astellas Pharma US INC | $119.08 | 2020-2024 | Veozah |
| Amgen INC. | $104.96 | 2019-2020 | |
| Coopersurgical, INC. | $102.39 | 2019-2023 | Endosee |
| Hologic Sales and Service, LLC | $71.53 | 2019-2023 | Novasure, Coolseal Generator |
| Novo Nordisk INC | $58.28 | 2023-2024 | Saxenda, Wegovy |
| Duchesnay USA Incorporated | $51.10 | 2019 | |
| Pfizer INC. | $34.22 | 2024 | |
| Medtronic, INC. | $29.90 | 2025 | Corevalve Evolut R |
| Sumitomo Pharma America, INC. | $24.69 | 2024 | Gemtesa |
| Radius Health, INC. | $24.01 | 2019-2020 | |
| Ascend Therapeutics US, LLC | $22.90 | 2021 | |
| Allergan, INC. | $22.86 | 2019-2020 | |
| Therapeuticsmd, INC. | $18.02 | 2019 | |
| Covidien LP | $17.77 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $15.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.99 | 2021 | |
| Exeltis, USA INC. | $14.78 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.49 | 2020 | |
| Lupin INC. | $13.74 | 2019 | |
| Lilly USA, LLC | $13.71 | 2024 | Zepbound |
| Currax Pharmaceuticals LLC | $13.58 | 2025 | Contrave |
| Minerva Surgical, INC | $12.86 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.21 | 2019 | |
| Merck Sharp & Dohme LLC | $12.20 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.